Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 03:01PM ET
14.62
Dollar change
-1.11
Percentage change
-7.06
%
IndexRUT P/E- EPS (ttm)-5.45 Insider Own1.72% Shs Outstand101.80M Perf Week-1.15%
Market Cap1.49B Forward P/E- EPS next Y-5.50 Insider Trans-0.22% Shs Float100.10M Perf Month-1.28%
Income-522.28M PEG- EPS next Q-1.34 Inst Own92.40% Short Float16.35% Perf Quarter-31.26%
Sales43.09M P/S34.56 EPS this Y1.95% Inst Trans7.79% Short Ratio6.96 Perf Half Y-37.12%
Book/sh9.46 P/B1.55 EPS next Y-3.51% ROA-43.22% Short Interest16.37M Perf Year-52.59%
Cash/sh6.46 P/C2.26 EPS next 5Y30.00% ROE-52.23% 52W Range12.82 - 34.87 Perf YTD-52.05%
Dividend Est.- P/FCF- EPS past 5Y-22.30% ROI-49.98% 52W High-58.07% Beta1.78
Dividend TTM- Quick Ratio6.73 Sales past 5Y12.09% Gross Margin76.36% 52W Low14.04% ATR (14)1.03
Dividend Ex-Date- Current Ratio6.73 EPS Y/Y TTM-1.73% Oper. Margin-1247.99% RSI (14)42.88 Volatility4.64% 6.77%
Employees526 Debt/Eq0.11 Sales Y/Y TTM-16.77% Profit Margin-1212.19% Recom1.50 Target Price59.08
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q2.55% Payout- Rel Volume0.74 Prev Close15.73
Sales Surprise10.00% EPS Surprise3.60% Sales Q/Q-24.02% EarningsNov 07 BMO Avg Volume2.35M Price14.62
SMA20-3.75% SMA50-14.62% SMA200-35.46% Trades Volume1,490,945 Change-7.06%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Downgrade Goldman Buy → Neutral $136 → $32
Feb-15-24Initiated Wolfe Research Peer Perform
Apr-13-23Initiated Canaccord Genuity Buy $66
Mar-21-23Initiated Bernstein Outperform $54
Mar-14-23Upgrade BMO Capital Markets Market Perform → Outperform $54 → $57
Feb-01-23Initiated Cantor Fitzgerald Overweight $67
Jan-24-23Upgrade Citigroup Sell → Neutral $48 → $39
Jan-19-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22Initiated Morgan Stanley Overweight $84
Sep-21-22Initiated JP Morgan Overweight $85
Nov-25-24 04:16PM
07:30AM
Nov-22-24 08:30AM
Nov-19-24 07:27AM
06:54AM
06:30AM Loading…
06:30AM
Nov-18-24 10:24AM
06:53AM
Nov-16-24 10:16AM
Nov-11-24 12:59PM
12:45PM
Nov-08-24 12:01PM
Nov-07-24 08:55AM
07:30AM
Nov-06-24 09:45AM
04:01PM Loading…
Nov-05-24 04:01PM
Nov-04-24 08:00AM
Oct-31-24 07:30AM
03:59AM
Oct-26-24 05:19PM
Oct-25-24 11:02AM
08:16AM
Oct-24-24 07:22PM
12:17PM
11:26AM
08:01AM
07:17AM
Oct-17-24 10:01AM
06:30AM
Oct-16-24 03:51PM
03:51PM Loading…
03:51PM
Oct-10-24 07:30AM
Oct-09-24 05:32PM
06:35AM
Oct-08-24 10:15AM
Oct-07-24 07:30AM
07:15AM
Oct-03-24 04:01PM
Oct-01-24 07:30AM
Sep-29-24 05:44AM
Sep-12-24 01:01PM
07:30AM
Sep-03-24 04:30PM
Aug-14-24 10:29AM
Aug-09-24 11:32AM
10:19AM
Aug-08-24 07:01PM
12:23PM
08:55AM
07:30AM
Aug-06-24 12:48PM
Aug-01-24 11:15AM
07:30AM
Jul-31-24 07:33AM
Jul-30-24 07:30AM
Jul-26-24 09:58AM
Jul-24-24 04:01PM
Jul-23-24 02:57PM
Jul-17-24 01:30PM
11:30AM
Jul-11-24 12:00PM
Jul-09-24 07:59AM
07:00AM
05:56AM
Jul-08-24 09:00AM
06:00AM
Jul-05-24 02:14PM
Jul-02-24 08:30AM
Jun-28-24 10:28AM
Jun-27-24 10:02PM
10:38AM
Jun-26-24 09:33PM
07:30AM
05:22AM
Jun-25-24 03:30PM
08:00AM
Jun-21-24 06:30AM
Jun-17-24 07:30AM
Jun-14-24 11:49AM
07:30AM
Jun-09-24 06:20AM
Jun-08-24 07:25AM
Jun-07-24 11:25AM
Jun-06-24 11:05AM
Jun-05-24 01:35PM
Jun-04-24 11:21AM
06:45AM
Jun-03-24 04:31PM
04:17PM
Jun-02-24 08:00AM
May-25-24 08:30AM
May-22-24 11:15AM
May-14-24 12:46PM
09:30AM
May-13-24 02:18PM
May-10-24 03:35PM
01:16PM
11:45AM
11:26AM
May-09-24 11:53PM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dube Michael PVP, Chief Accounting OfficerOct 02 '24Sale19.012,01238,24847,012Oct 04 05:29 PM
Clark ElianaEVP, Chief Technical OfficerJul 01 '24Sale22.934059,28771,470Jul 03 01:15 PM
Verwiel FrankDirectorJun 17 '24Sale25.001,50537,62517,948Jun 20 05:00 PM
BASTA JAMESEVP, General CounselMar 04 '24Sale32.992,29775,77881,571Mar 05 04:10 PM
Clark ElianaEVP, Chief Technical OfficerMar 04 '24Sale32.9960519,95971,470Mar 05 04:10 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 08 '24Sale28.872,27565,68243,927Jan 10 04:15 PM
LEONARD JOHN MPresident and CEOJan 03 '24Sale29.4619,223566,310846,486Jan 05 04:51 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 03 '24Sale29.465,843172,13554,372Jan 05 04:50 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 03 '24Sale29.465,532162,97346,202Jan 05 04:50 PM
Goddard GlennEVP, Chief Financial OfficerJan 03 '24Sale29.465,365158,05340,585Jan 05 04:49 PM
Hicks DerekEVP, Chief Business OfficerJan 03 '24Sale29.463,877114,21636,987Jan 05 04:46 PM
BASTA JAMESEVP, General CounselJan 03 '24Sale29.463,805112,09551,474Jan 05 04:45 PM
Clark ElianaEVP, Chief Technical OfficerJan 03 '24Sale29.504,608135,95440,845Jan 05 04:44 PM